MKTW heads into its May 7 Q1 print with a split signal: founder buying pushing against rising short interest and a freshly announced dividend.
The most telling insider move came in mid-to-late March, when founder Frank Porter Stansberry purchased roughly 40,000 shares across three transactions at prices between $14.28 and $15.76 — committing just under $600,000 of his own capital. That accumulation, at levels well below the current $17.41 close, lifted the 90-day net insider position to approximately 75,100 shares with a net value around $1.1 million. The CFO, Erik Mickels, was moving in the opposite direction over the same period, selling roughly 21,000 shares in a series of smaller transactions. The contrast is notable: the company's founder is buying, while its finance chief is trimming. Both trades carry modest significance scores, but the direction divergence is worth flagging ahead of the print.
Short interest adds another layer. The estimated short position jumped 35% over the past week to 1.27% of the float — a level that remains low in absolute terms but has accelerated sharply, with a 17% single-session spike on May 4 drawing attention. At just 0.65% cost to borrow and with ample availability still in the lending market, there is no meaningful squeeze pressure here; the borrow market is loose rather than tight. The ORTEX short score of 31 is mid-range, and neither utilization nor availability points to any dislocation. The short interest move looks more like tactical positioning ahead of the release than a conviction bet against the stock.
The bull-versus-bear tension into the print centres on capital return versus business fundamentals. MarketWise declared a special dividend of $0.20 per share in early March, and the company's dividend score ranks at the 84th percentile — a signal that income investors have reason to pay attention. The stock carries a negative enterprise value, pointing to a cash-heavy balance sheet, and the P/B multiple is also negative, reflecting a shareholder equity structure that can confuse traditional valuation screens. The one analyst target in the data (UBS, Neutral, $20 target from August 2025) is too stale to carry much weight here. The stock has fallen roughly 8% over the past month to close at $17.41, despite a 3.9% bounce on May 5 — suggesting the market has been cautious, not euphoric, coming into results. Past prints have been muted: the two most recent earnings events produced moves of roughly +8% and -1.7% on the day respectively, with the five-day reaction drifting mildly negative after the former.
The Q1 report is therefore less about whether MarketWise is growing and more about whether the company's subscriber trends and cash generation can justify sustaining its dividend at a level that the founder appears to believe undervalues the stock at current prices.
See the live data behind this article on ORTEX.
Open MKTW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
